NewLimit raises $435M, valuation hits $3.1B ahead of trial

A biotechnology startup focused on developing treatments to reverse cellular aging has secured a significant new investment, dramatically increasing its valuation as it prepares for its first human clinical trial. NewLimit, co-founded by Coinbase CEO Brian Armstrong, announced it closed a $435 million Series C funding round led by Founders Fund. The investment places the company’s post-money valuation at approximately $3.1 billion, which is roughly triple its valuation from less than a year ago.

The funding round included participation from new investors Thrive Capital, Greenoaks, and Quiet Capital, while returning backers such as Kleiner Perkins and Abstract also contributed. NewLimit, founded in 2021 by Armstrong alongside Blake Byers and CEO Jacob Kimmel, is pursuing therapies based on epigenetic reprogramming. This scientific approach aims to reset gene expression patterns in aged cells to more youthful states without altering the underlying DNA, with the goal of treating age-related diseases.

Company officials stated that accelerated progress in its research program prompted the rapid valuation increase and the push toward human trials. NewLimit has developed a prototype...